QY201 for Eczema: What a 200-Adult Phase 2 Trial Found

November 9, 2026

AI-generated illustration: Dr. Arsy #003 courtside essentials

Dr. Arsy Editorial Team · November 9, 2026

QY201 is an investigational oral inhibitor of JAK1 and TYK2. A phase 2 trial asked whether three twice-daily doses could improve moderate-to-severe atopic dermatitis over 12 weeks. It is an early development study, not evidence that QY201 is approved, appropriate for a particular person, or safer than established options.^[1]

How the trial was designed

Researchers randomized 200 adults to QY201 5 mg, 10 mg, 20 mg twice daily, or placebo. The primary endpoint was EASI-75 at week 12, meaning at least a 75% improvement from baseline in the Eczema Area and Severity Index. Dose-finding trials help select regimens for later confirmatory testing; they generally cannot settle longer-term safety, durability, or comparative effectiveness.

What the numbers showed

Week-12 EASI-75 responses were 72.9%, 84.7%, and 81.4% across the three QY201 groups, compared with 18.5% for placebo. Investigator Global Assessment responses also favored QY201. Treatment-emergent adverse events were reported in 74.0%, 75.5%, and 90.4% of the active groups and 69.4% of the placebo group. Most were described as mild or moderate, but the highest-dose group’s event frequency is one reason the efficacy percentages should not be read alone.^[1]

Why this is not a head-to-head ranking

The trial did not compare QY201 directly with an approved JAK inhibitor, biologic, phototherapy, or optimized topical care. Cross-trial comparisons are vulnerable to differences in baseline severity, rescue rules, geography, missing-data methods, and placebo response. Broader meta-analyses can help map a treatment landscape, but they still cannot replace a randomized head-to-head study.^{[9][10][11][20][21][22]}

Questions that phase 3 studies must answer

Are responses maintained beyond 12 weeks?
Which dose offers the most favorable benefit-risk balance?
What uncommon or delayed safety outcomes appear with larger exposure?
How do patient-reported itch, sleep, quality of life, and treatment burden change?
Will results generalize beyond the single-country phase 2 population?

People with uncontrolled eczema should discuss approved options with a qualified clinician. Do not obtain or use an investigational medicine outside an authorized research or regulatory pathway.

Where Dr. Arsy #003 fits

Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not tested in the study reviewed here and should not be described as producing the study treatment’s effects. It does not diagnose, treat, cure or prevent eczema.

Continue reading

Research and clinical references

Educational information only; not a diagnosis or personalized medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.

← Back to Doctor's Notes